Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Net Cash Flow (2018 - 2025)

TransMedics has reported Net Cash Flow over the past 8 years, most recently at $22.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $22.1 million for Q4 2025, up 205.09% from a year ago — trailing twelve months through Dec 2025 was $150.4 million (up 361.07% YoY), and the annual figure for FY2025 was $150.4 million, up 361.07%.
  • Net Cash Flow for Q4 2025 was $22.1 million at TransMedics, down from $65.6 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TMDX hit a ceiling of $386.8 million in Q2 2023 and a floor of -$155.2 million in Q3 2023.
  • Median Net Cash Flow over the past 5 years was $503000.0 (2021), compared with a mean of $23.2 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 6821.28% in 2022 and later tumbled 772.79% in 2023.
  • TransMedics' Net Cash Flow stood at $3.4 million in 2021, then crashed by 210.18% to -$3.7 million in 2022, then tumbled by 772.79% to -$32.6 million in 2023, then surged by 122.22% to $7.2 million in 2024, then surged by 205.09% to $22.1 million in 2025.
  • The last three reported values for Net Cash Flow were $22.1 million (Q4 2025), $65.6 million (Q3 2025), and $89.6 million (Q2 2025) per Business Quant data.